Loss‐of‐function mutations in the <i>ALPL </i>gene presenting with adult onset osteoporosis and low serum concentrations of total alkaline phosphatase by Alonso, Nerea et al.
  
 
 
 
Edinburgh Research Explorer 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Lossoffunction mutations in the ALPL gene presenting with adult
onset osteoporosis and low serum concentrations of total
alkaline phosphatase
Citation for published version:
Alonso, N, Larrazprieto, B, Berg, K, Lambert, Z, Redmond, P, Harris, SE, Deary, IJ, Pugh, C, Prendergast, J
& Ralston, SH 2020, 'Lossoffunction mutations in the ALPL gene presenting with adult onset osteoporosis
and low serum concentrations of total alkaline phosphatase', Journal of Bone and Mineral Research, vol.
35, no. 4, pp. 657-661. https://doi.org/10.1002/jbmr.3928
Digital Object Identifier (DOI):
10.1002/jbmr.3928
Link:
Link to publication record in Edinburgh Research Explorer
Document Version:
Publisher's PDF, also known as Version of record
Published In:
Journal of Bone and Mineral Research
General rights
Copyright for the publications made accessible via the Edinburgh Research Explorer is retained by the author(s)
and / or other copyright owners and it is a condition of accessing these publications that users recognise and
abide by the legal requirements associated with these rights.
Take down policy
The University of Edinburgh has made every reasonable effort to ensure that Edinburgh Research Explorer
content complies with UK legislation. If you believe that the public display of this file breaches copyright please
contact openaccess@ed.ac.uk providing details, and we will remove access to the work immediately and
investigate your claim.
Download date: 12. Jun. 2020
ORIGINAL ARTICLE
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ABSTRACT
Hypophosphatasia (HPP) is a rare inherited disorder characterized by rickets and low circulating concentrations of total alkaline phos-
phatase (ALP) caused by mutations in ALPL. Severe HPP presents in childhood but milder forms can present in adulthood. The prev-
alence and clinical features of adult HPP are poorly defined. The aim of this study was to evaluate the prevalence and clinical
significance of low serum total alkaline phosphatase (ALP) levels in a clinic-based population of adult osteoporotic patients. We
searched for patients with low ALP in a cohort of 3285 patients referred to an osteoporosis clinic over a 10-year period and performed
mutation screening of ALPL in those with low ALP (≤40 U/L) on two or more occasions. These individuals were matched with four
clinic controls with a normal ALP. We also evaluated the prevalence of low ALP and ALPLmutations in 639 individuals from the gen-
eral population from the same region. We identified 16/3285 (0.49%) clinic patients with low ALP and 14 (87.5%) had potentially path-
ogenic variants in ALPL. Eight of these individuals were heterozygous for mutations previously described in HPP and 2 were
heterozygous for novel mutations (p.Arg301Trp and p.Tyr101X). These mutations were not found in clinic controls or in the general
population. Eight patients with low ALP, including 4 with ALPL mutations, were treated with bisphosphonates for an average of
6.5 years. In these individuals, the rate of fractures during treatment was comparable to that in normal ALP clinic controls who were
treated with bisphosphonates. We conclude that heterozygous loss-of-function mutations in ALPL are common in osteoporosis
patients with low ALP. Further studies are required to determine how best these individuals should be treated. © 2019 The Authors.
Journal of Bone and Mineral Research published by American Society for Bone and Mineral Research.
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Introduction
Hypophosphatasia (HPP) is a rare inherited disorder charac-terized by low circulating concentrations of total alkaline
phosphatase (ALP), rickets, muscular hypotonia, seizures, and
multiple fractures.(1) The severity of the disease ranges widely
from a severe, recessively inherited disorder presenting neona-
tally, which until recently was fatal without treatment, to milder
forms that can present later in childhood or in adults. In Europe,
severe HPP has been estimated to affect about 1 in 300,000
individuals.(2)
Adults with HPPmay present with osteomalacia, osteoporosis,
fragility fractures, and dental problems. Atypical femoral frac-
tures have been reported in some patients who have been trea-
ted with bisphosphonates.(3–6) The prevalence and mode of
clinical presentation in adults with HPP is unclear. It has been
suggested to affect about 1 in 6000 individuals(2) but may be
more common due to the diagnosis being overlooked.(7)
The cause of HPP is loss-of-function or dominant negativemuta-
tions in ALPL.(8) Based on the population prevalence of recessive
HPP, the proportion of dominant mutations, and the penetrance
of the ALPL mutations,(2) one would expect about 1 in
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500 individuals in the general population to be carriers, although it
is unclear to what extent these individuals are symptomatic.(9) The
ALPL gene encodes the tissue-nonspecific ALP, a 50 kDa protein
expressed in bone, liver, and kidney. In bone, it is essential for the
mineralization process, because it hydrolyzes pyrophosphate, an
inhibitor of hydroxyapatite formation and, at the same time,
releases inorganic phosphate, which combineswith calcium to pro-
mote mineralization.(10) To date, at least 397 variants have been
described in this gene as causing HPP (as reported in The Tissue
Nonspecific Alkaline Phosphatase Gene Mutation Database).(11)
Most are missense mutations found in homozygous or compound
heterozygous form. Additionally, low-frequency, heterozygousmis-
sense variants in ALPL have been observed in men with low bone
mineral density(12) and at low frequency in adults with various rheu-
matologic disorders, including osteoarthritis, rheumatoid arthritis,
Castleman disease, and patients with recurrent fractures.(13)
The prevalence of low ALP levels and its clinical significance in
osteoporotic patients have not yet been studied. Therefore, the
aim of this study was to investigate how frequently low ALP
occurs in patients with osteoporosis and to determine the pro-
portion of these individuals who have mutations in ALPL.
Materials and Methods
The study was based at the osteoporosis clinic at theWestern Gen-
eral Hospital in Edinburgh (UK), which is a secondary care referral
center for patients with bone disease. In this clinic, total ALP con-
centrations are measured in all patients as part of a routine bio-
chemical screen in the NHS Lothian laboratories. In keeping with
the suggestion by Lee and colleagues,(14) we derived an assay-
specific reference range for ALP by analysis of samples from
200 healthy controls from the local population. We searched the
clinic database for individuals who had ALP values below the lower
limit of the reference range (≤40 U/L) on two or more occasions.
We also screened a population-based cohort from the same
region—the Lothian Birth Cohort of 1936 (LBC1936)(15) —for low
ALP levels that had been measured on two occasions by the same
laboratory as part of a routine biochemical screen (n= 639). In both
cohorts, we screened for coding variants of ALPL according to stan-
dard techniques. Full details of the genotyping methodologies
used are provided in the Supplemental Materials and Methods.
Comparison between groups for categorical variables was by
chi-square test or Fisher’s exact test and by nonparametric
Mann–Whitney U test for continuous variables, with the excep-
tion of fractures per patient per year, which was calculated using
the Kruskal-Wallis test. The p value for significance was set at
0.05. Statistical analysis of the data was performed using SPSS
version 21 (IBM Corp., Armonk, NY, USA).
Results
Clinical characteristics of low ALP cases and clinic controls
A search of the osteoporosis clinic database identified 16/3285
(0.49%) individuals with low ALP values (≤40 U/L) on at least
two occasions. The clinical characteristics of patients with low
ALP levels were similar to those of clinic controls in terms of bone
mineral density (BMD), fracture history, smoking, alcohol intake,
and comorbidity (Table 1). Eight individuals with low ALP had
been treated with bisphosphonates before being referred to
the clinic (6 with alendronic acid and 2 with risedronate), but
serum ALP levels were low in 7 of these individuals before start-
ing bisphosphonates. In 1 patient, ALP had not been checked
before starting risedronate (Table 1). The mean  SD ALP values
before starting bisphosphonate therapy in the 7 individuals
where data were available was 34  6.07 U/L compared with
29  4.01 U/L at the time of clinic referral, a difference that was
not significant (p = 0.11). None of the individuals with low ALP
had clinical features to suggest hypophosphatasia, such asmeta-
tarsal fractures, atypical femoral fracture, chondrocalcinosis, pre-
mature tooth loss, or a family history of HPP.
By way of comparison, 18/64 (28.1%) of controls had previously
received bisphosphonate, a proportion that was not significantly
different from low ALP cases (p = 0.10). Serum albumin concentra-
tions were marginally lower in those with low ALP (4.04  0.07
versus 4.29  0.05 g/L, p = 0.009), but no differences were
observed in other routine biochemistry (not shown). One clinic
control with normal ALP values had presented an atypical femoral
fracture associated with bisphosphonate treatment.
Genetic analysis of low ALP cases and clinic controls
We found that 14/16 (87.5%) individuals with low ALP had poten-
tially pathogenic variants in ALPL (Table 2 and Supplemental
Table S3). Eight patients had ALPL mutations that have already
been reported in HPP and2 further patients had novel variants pre-
dicted to be pathogenic (c.303c > a, causing a nonsense change p.
Tyr101X, and c.901a > t, encoding a missense mutation p.
Arg301Trp). All variants were found in heterozygous form. The fre-
quency of ALPL mutations in the low ALP clinic cases was signifi-
cantly higher than in the clinical controls with normal ALP
Table 1. Clinical Characteristics of Low ALP Clinic Cases and
Controls
Clinical characteristics
Low ALP
cases
(n = 16)
Normal ALP
controls
(n = 64)
Age (years) 66  3.0 64  1.3
Body mass index (kg/m2) 23.4  1.2 24.9  0.7
ALP (U/L) 29.7  0.82 88.0  1.7*
Previous bisphosphonate
therapy, n (%)
8 (50) 18 (28.1)
Female sex, n (%) 13 (81.2) 52 (81.2)
Age at menopause (years) 49  1.6 46  1.0
Serum 25-vit D (nmol/L) 54.7  11.8 51.3  5.5
Serum albumin (g/dL) 4.04  0.07 4.29  0.05**
Estimated glomerular
filtration rate (mL/min)
56.5  2.5 59.4  0.6
Alcohol intake (units) 5.7  1.8 6.2  1.2
Smoker, n (%) 1 (6.2) 18 (28.1)
Lumbar spine bone
mineral density (BMD)
0.731  0.03 0.797  0.02
Femoral neck BMD 0.589  0.02 0.621  0.03
Total hip BMD 0.716  0.02 0.686  0.03
FRAX major fracture 16.1  2.10 14.2  1.14
FRAX hip fracture 6.3  1.64 4.9  0.67
Age at first fracture (years) 62.3  3.8 61.1  2.2
Nonvertebral fractures,a n (%) 8 (50.0) 24 (37.5)
Vertebral fracture, n (%) 8 (50.0) 23 (36.0)
Early menopause, n (%) 3 (18.7) 8 (12.5)
Charlson index 3.06  0.64 3.11  0.24
aLow-trauma fractures validated by X-ray.
*p = 7.30 × 10−10.
**p = 0.009.
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(p = 4.86 × 10−9). Four low ALP clinic patients carried the p.
Arg152His polymorphism compared with 1 normal ALP clinic con-
trol (1.5%), a difference that was significant (p = 0.005). The variants
were located at different sites in the ALP protein, many affecting
regions of functional importance (Fig. 1). In silico analysis of themis-
sense p.Arg301Trp variant predicted that the change was patho-
genic (Supplemental Table S2). The variant affects amino acid
301, which is within a Ca++ binding site of the protein (Fig. 1) and
which is highly conserved through evolution (Supplemental Fig. S1).
In addition to these functional variants, we found a commonbenign
variant (p.Val522Ala, rs34605986) in 2/16 (12.5%) low ALP patients
and 17 clinic controls (26.5%), a difference that was not significant.
Frequency of low ALP and ALPL variants in the general
population
We identified 6/639 individuals (0.9%) with low ALP (≤40 U/L) in
the LBC1936 cohort. None of the individuals in LBC1936 were
known to have a diagnosis of HPP and none had reported pre-
mature tooth loss. Information on AFF, metatarsal fractures,
Table 2. Variants Found in ALPL Gene in Clinic Patients With Low ALP
ID ALPa (U/L) ALPL variant Exon Protein change Comment
1 32 c.575 t > c 6 p.Met192Thr Infantile HPP; compound heterozygote (SESEP-University
of Versailles-Saint Quentin)
2 27.5 c.303c > a 4 p.Tyr101X Novel
3 32.5 c.668 g > a 7 p.Arg223Gln Perinatal HPP; found with a large deletion(16,17)
4 29.5 c.455 g > a 5 p.Arg152His Polymorphism; affecting a residue involved in
odonto-HPP(18) low BMD(12)
5 34 c.920c > t 9 p.Pro307Leu Infantile HPP; compound heterozygote (SESEP-University
of Versailles-Saint Quentin)
6 26 c.1171c > t 10 p.Arg391Cys Childhood HPP; compound heterozygote(19,20)
7 34.5 c.455 g > a 5 p.Arg152His Polymorphism; affecting a residue involved in
odonto-HPP;(18) low BMD(12)
8 21.5 c.436 g > a 5 p.Glu146Lys Asymptomatic; low BMD(12)
9 29.5 - - -
10 33 c.436 g > a 5 p.Glu146Lys Asymptomatic; low BMD(12)
11 28.5 c.901a > t 9 p.Arg301Trp Novel
12 30 - - -
13 32.5 c.455 g > a 5 p.Arg152His Polymorphism; affecting a residue involved in
odonto-HPP;(18) low BMD(12)
14 26 c.1120 g > a 10 p.Val374Met Adult HPP; compound heterozygote (SESEP-University of
Versailles-Saint Quentin(17))
15 28.5 c.1348c > t 12 p.Arg450Cys Infantile HPP; homozygous(20,21)
16 30 c.455 g > a 5 p.Arg152His Polymorphism; affecting a residue involved in
odonto-HPP;(18) low BMD(12)
aMean of two independent ALP readings.
Fig. 1. Location of the ALPL variants found in this study. The location of pathogenic missense variants found in osteoporotic patients with low ALP levels
are highlighted in red. The protein sequence and domains have been adapted from Silvent and colleagues.(22)
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and chondrocalcinosis was not available. Genetic analysis identi-
fied the p.Arg152His polymorphism (rs149344982) in heterozy-
gous form in 31/639 (4.8%) participants in LBC1936. Individuals
carrying the “A” variant (encoding Histidine) had significantly
lower levels of ALP than those with the “G” variant, encoding
Arginine (mean  SEM ALP = 60.4  3.2 versus 79.0  1.2 U/L;
p = 3.58 × 10−4). Two of the 31 individuals with the “A” variant
showed low ALP levels (≤40 U/L). No individuals in the 1936
LBC cohort were found to have ALPL mutations.
The p.Val522Ala polymorphism (rs34605986) was found in
18.5% of LBC1936, in both homozygous and heterozygous
forms. No significant differences in ALP levels were found
between individuals of different genotype (ALP = 77.7  1.30
for the TT genotype; 79.3  2.01 for the CT genotype,
81.1  6.4 for the CC genotype, p value = 0.836).
Treatment and clinical outcome in low ALP cases and
controls
Details of the treatments given to the low ALP cases and controls
are shown in Table 3. Bisphosphonates were themost commonly
prescribed treatment in both groups. During follow-up of up to
9 years, there was no significant difference between the patients
with low ALP and controls in the proportion of patients who had
suffered one or more fractures. One atypical femoral fracture was
observed in the control group.
Discussion
We have found that about 0.5% of patients attending our osteo-
porosis clinic had low circulating concentrations of ALP and that
the majority of these individuals had pathogenic mutations in
ALPL. Although 8 patients had previously been treated with
bisphosphonates, 7 of these individuals had ALP measured
before starting treatment and it was low in all cases. In 8/16 clinic
cases with low ALP, known loss-of-function mutations in ALPL
were found and, in a further 2 cases, novel variants were found
and predicted to be pathogenic by bioinformatic techniques. In
all cases, these variants were found in heterozygous form, and
most were located in functionally important domains of the pro-
tein: the Ca++ binding domain, which is crucial for the main func-
tion of the ALP protein (p.Arg223Gln, p.Pro307Leu); the crown
domain, involved in binding to collagen (p.Arg391Cys, p.
Arg450Cys); and the homodimeric domain, which binds ALP to
form the active homodimer (p.Arg391Cys, p.Arg450Cys). The p.
Arg391Cys variant also affects a residue that is thought to be
subject to phosphorylation.(22) The two novel variants identified
in our study, p.Tyr101X and p.Arg301Trp, were also classified as
pathogenic based on the criteria suggested by the American Col-
lege of Medical Genetics and the Association for Molecular
Pathology.(23) In another 4 cases, a missense variant was
observed (p.Arg152His). This change has been previously
reported as a polymorphism in HPP cases but associated with
low ALP and low BMD in a previous study.(12) It also affects the
residue 152, a mutation hotspot also harboring p.Arg152Cys,
which has previously been reported to worsen an odonto-HPP
phenotype.(18) In our study, the p.Arg152His variant was overrep-
resented in people with low ALP in both cohorts and was associ-
ated with a reduced ALP concentration in the LBC1936 cohort.
Because many individuals who carried the p.Arg152His polymor-
phism had ALP values in the normal range, it seems likely that in
a subgroup of individuals, other environmental or genetic regu-
lators of ALP may have acted in combination with this polymor-
phism to push ALP values below the lower limit of normal.
Whatever the underlying mechanism, the data presented here
support the view that p.Arg152His may be a functional variant
that impairs ALP activity. Altogether, our results are consistent
with previous findings of adults with persistently low levels of
ALP, where 50% to 84% of individuals were found to carry coding
variants in ALPL.(24,25)
Some missense variants in ALPL have been proposed to exert
dominant negative effect on enzyme function, especially those
located within functional domains.(9) However, only the p.
R391C variant has been tested for this in vitro with negative
results.(19) The results reported here support the view that the
missense variants impair ALP function, but further research will
be required with each variant to determine if this is due to a
dominant negative effect or haploinsufficiency.
Within the clinic population, patients with low ALP tended to
have lower BMD values than clinic controls with normal ALP.
Although the differences were not significant, the number of
patients with low ALP was small. Those with low ALP also had
slightly lower serum albumin concentrations but did not have
any other distinguishing clinical or biochemical characteristics.
It is of interest, however, that missense variants in ALPLwere sig-
nificantly overrepresented in the osteoporosis clinic population
with low ALP values compared with the general population, indi-
cating that these variants may be a predisposing factor for
osteoporosis.
To date, the only treatment approved for patients with HPP is
bone-targeted enzyme-replacement therapy with asfotase
alfa.(9) Bisphosphonates are generally considered to be contrain-
dicated in HPP because they can inhibit mineralization and
because bisphosphonate treatment of adult patients with mild
HPP has been associated with atypical femoral fractures.(6,9,26,27)
Table 3. Treatment and Clinical Outcome in Low ALP Cases and
Clinic Controls
Treatments
Cases
(n = 16)
Controls
(n = 64) p Value
Alendronic acid 8 (50.0%) 37 (56.1%)
0.22
Risedronate 0 (0%) 5 (7.6%)
Zoledronic acid 2 (14.2%) 10 (15.1%)
Denosumab 2 (14.2%)) 3 (4.5%)
Teriparatide 1 (7.6%) 0 (0%)
Hormone replacement
therapy
0 (0%) 1 (1.5%)
No treatment 3 (21.8%) 10 (15.1%)
Duration of follow-up
(years)
6.5  3.4 9.2  2.6 0.001
Fractures during
follow-up
0.28
No fractures 10 (71.4%) 33 (50.0%)
1 fracture 3 (21.4%) 18 (27.3%)
2 fractures 1 (7.1%) 11 (16.7%)
3 fractures 0 (0%) 4 (6.1%)
Fracture/patient/year 0 (0–0.07) 0.04 (0–0.17) 0.09
Atypical femoral
fractures
0 (0%) 1 (1.6%) 1.0
Values are mean  SD or n (%), except fractures/patient/year, which
shows median and interquartile ranges. The p values refer to differences
between groups calculated by chi-square test or Fisher’s exact test (frac-
ture and treatments), t test (duration of follow-up), and fractures per
patient per year (Kruskal–Wallis test).
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In this study, 10 patients with potentially damaging ALPL vari-
ants and osteoporosis had been treated with bisphosphonates
and were followed up for an average of just over 6 years.
Although the sample size was small, we found no evidence to
suggest that patients with ALPL variants treated with bispho-
sphonates fared any worse than those without these variants,
given that the number of low-trauma fractures during follow-
up were similar in the two groups. One patient developed an
atypical femoral fracture while on bisphosphonate therapy, but
that individual had a normal level of ALP and had no deleterious
variants in ALPL. Nonetheless, we think it would be appropriate
to be cautious in treating patients who have low ALP with using
bisphosphonates until further information is available on clinical
outcomes from larger cohorts of patients to confirmwhether this
is the optimal mode of treatment for these patients.
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